Tagged with IRPMA

Taiwan Taiwan is, in many ways, a healthcare model for Asia. The island has had universal health coverage for over 30 years and Taiwan’s life expectancy today is almost 81 years, putting it behind only Japan, South Korea, and Singapore in its region. However, by the early 2020s, this rapidly ageing…

Taiwan Taiwan’s healthcare system stands among the most advanced and accessible in Asia, yet, as the IRPMA’s CW Chen points out, sustainability is now the central concern. Drawing on a career that has spanned leadership roles at Chugai Pharma Taiwan, GSK, and Abbott Taiwan, Chen brings a uniquely comprehensive view of…

International Research-Based Pharmaceutical Manufacturers’ Association (IRPMA) General Manager, Chugai Pharma Taiwan and President of International Research-Based Pharmaceutical Manufacturers’ Association (IRPMA), discusses the continuous price cuts that plague the Taiwan market, and how IRPMA is getting involved in the discussions with the government on how to rectify this growing problem. During our interviews, general managers heading IRPMA…

Array The latest details regarding Article 46, a key piece of legislation attached to the second-generation health insurance reform, were announced this week. What are the key points to take away from this announcement? In Taiwan, the government is attempting to limit the growth of annual spending on pharmaceuticals—an expenditure that…

IRPMA (International Research-Based Pharmaceu Please describe the activities of the IRPMA to our readers, and explain the membership advantages of your association. Today the IRPMA consists of 37 multinational research-based pharmaceutical manufacturers, as well as some local R&D companies. Also, eleven individual members representing distribution and start-up biotech companies registered IRPMA for their preparation…